Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.

Fiche publication

Date publication

mars 2017

Journal

British journal of clinical pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SCHOTT Roland , Dr ZANETTA Sylvie , Pr REIMUND Jean-Marie

Tous les auteurs :
Dupont B, Mariotte D, Dugué AE, Clarisse B, Grellard JM, Babin E, Chauffert B, Dakpé S, Moldovan C, Bouhier-Leporrier K, Reimund JM, Di Fiore F, Zanetta S, Mailliez A, Do P, Peytier A, Galais MP, Florescu C, Schott R, Le Mauff B, Gervais R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27662818

Résumé

Cetuximab is an anti-epidermal growth factor receptor antibody used for the treatment of metastatic colorectal cancer and head and neck cancer. Hypersensitivity reactions (HSRs) are associated with cetuximab use. The aim of the study was to evaluate the utility of anti-cetuximab immunoglobulin E (IgE) detection in order to identify patients at risk of HSR to cetuximab.